Shimadzu Releases Amyloid MS CL System for Measuring Candidate Substance Potentially Causing Alzheimer’s DiseaseSystem Requires Testing Only a Small Quantity of Blood, which Reduces Burden to Patients July 21, 2021 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Shimadzu Releases Amyloid MS CL System for Measuring…Shimadzu Releases the SyncTraX™ (SMART…[Ad hoc announcement pursuant to Art. 53 LR] Roche’s…Roche's Elecsys Amyloid Plasma Panel granted…Roche provides update on Alzheimer’s Prevention…Making Nissui Pharmaceutical as a Wholly-Owned…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
